title: Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.
abstract: Acting on keratinocytes to produce antimicrobial peptides and chemokines, which in turn attract neutrophils and other inflammatory cells, interleukin-17 (IL-17) is believed to be a potent driver of plaque psoriasis. Its proinflammatory characteristics make IL-17 an attractive therapeutic target for addressing immune dysregulation. This review examines the role of IL-17 in the pathogenesis of plaque psoriasis and the potential implications of its inhibition. The efficacy and safety results from Phase 2 and 3 trials with monoclonal antibodies targeting IL-17RA (brodalumab), and IL-17A (ixekizumab and secukinumab) validate IL-17 as an effective therapeutic target for the treatment of plaque psoriasis.
authors: Skin Centre for Dermatology, Peterborough, ON, Canada; Probity Medical Research, Waterloo, ON, Canada.
authors: Melinda
authors: M
authors: Gooderham
authors: Skin Centre for Dermatology, Peterborough, ON, Canada.
authors: Claudia J
authors: CJ
authors: Posso-De Los Rios
authors: Skin Centre for Dermatology, Peterborough, ON, Canada; Division of Dermatology, University of Toronto, Toronto, ON, Canada.
authors: Gustavo A
authors: GA
authors: Rubio-Gomez
authors: K. Papp Clinical Research, Waterloo, ON, Canada; Probity Medical Research, Waterloo, ON, Canada.
authors: Kim
authors: K
authors: Papp
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D020381:Interleukin-17 / Q000037:antagonists & inhibitors*; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D020381:Interleukin-17; C571216:brodalumab; C549079:ixekizumab; C555450:secukinumab